Healthcare Industry News:  Oxiplex 

Devices Surgery

 News Release - November 16, 2006

Comprehensive Review Published on FzioMed Technology for Postsurgical Adhesion Prevention

SAN LUIS OBISPO, Calif.--(HSMN NewsFeed)--FzioMed, Inc. reported today that a review of the company's technology for postsurgical adhesion prevention has been published in The Journal of Biomedical Material Research, Wiley Periodicals, Inc.

The article, "A Modern Biomaterial for Adhesion Prevention" (J Biomed Mater Res Part B: Appl Biomater, 2006 DOI 10.1002/jbm.b.30659), describes FzioMed's proprietary biomaterials platform, known as Oxiplex®, and the promising clinical results using Oxiplex products for adhesion prevention in gynecologic and spine surgery.

Postoperative adhesions are abnormal bands of scar tissue that can form inside the body after surgery. Adhesion formation is considered the single greatest complication of surgery. Adhesions form in nearly all patients undergoing gynecologic surgery and lead to increased rates of reoperation, postoperative bowel obstruction, infertility and chronic pelvic pain. Adhesions following spine surgery cause recurrent back pain and weakness and can compromise an otherwise successful outcome.

FzioMed's technology is based on the patented combination of two safe, absorbable medical polymers, carboxymethylcellulose and polyethylene oxide. The company combines these materials to create products customized for different body cavities and surgical applications.

FzioMed's adhesion prevention products are injectable gels used intraoperatively to coat tissues and reduce the extent and severity of adhesions. The gels are easy to use during surgery in the peritoneal cavity as well as the lumbar spine and clinical studies found both peritoneal and peridural formulations to be safe and effective. The article concluded that FzioMed products have "provided a benefit to patients undergoing surgery where postsurgical adhesion formation is a concern." In addition to their benefits as devices, the gels may also be effective vehicles for drug delivery for many unmet problems of surgical therapeutics.

About FzioMed

FzioMed is a medical company developing and commercializing absorbable, surgical biomaterials based on the company's patented Oxiplex science. Oxiplex is an innovative medical polymer technology with uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include the leading adhesion barrier for spine surgery currently marketed outside of the United States as Oxiplex®/SP Adhesion Barrier Gel and as MediShield(TM) Anti-Adhesion Gel, Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse(TM) cosmetic dermal filler. FzioMed products are for investigational use only in the U.S. Go to www.fziomed.com.

FzioMed®, Oxiplex® and Laresse(TM) are trademarks of FzioMed, Inc., and MediShield(TM) is a trademark of Medtronic Sofamor Danek.


Source: FzioMed

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.